Download the Case Study
Advancing a First-in-Class Vaccine in Kidney Transplantation
Advancing a First-in-Class Vaccine in Kidney Transplantation
Advancing a First-in-Class Vaccine in Kidney Transplantation
Kidney transplantation is the gold-standard therapy for End-Stage Kidney Disease (ESKD), yet post-transplant complications and graft dysfunction remain major drivers of long-term morbidity. New treatments, such as vaccines that protect transplant recipients from infection and reactivation of dormant viruses, are a key focus in transplant medicine. However, conducting clinical trials in this population is uniquely challenging.
The following case study outlines Medpace’s successful approach to a global clinical trial evaluating an investigational intramuscular vaccine administered pre-transplant.
Your Next Breakthrough Starts Here
Leading Transplantation CRO
Medpace brings deep expertise and global execution to transplantation clinical development, spanning solid organ (e.g., renal, hepatic) and hematopoietic stem cell transplantation. Our multidisciplinary teams — including in-house nephrologists, infectious disease specialists, and immunologists — partner with Sponsors to accelerate programs that aim to improve graft survival, minimize rejection, and advance post-transplant outcomes.